Similar articles

• [Study of the durability of the triple antiretroviral regimens].

  Martínez Sesmero JM, Sánchez-Rubio Ferrández J, Ontañón Nasarre A, Ibáñez Heras N, Montojo Guillén C. Martínez Sesmero JM, et al. Med Clin (Barc). 2004 May 15;122(18):693-5. doi: 10.1016/s0025-7753(04)74358-4. Med Clin (Barc). 2004. PMID: 15171829 Spanish.
• First-line HIV therapy shall not fail.

  Boucher C, Vella S. Boucher C, et al. Lancet HIV. 2016 Mar;3(3):e108-9. doi: 10.1016/S2352-3018(16)00022-9. Epub 2016 Feb 16. Lancet HIV. 2016. PMID: 26939732 No abstract available.
• Highly active antiretroviral therapy and beta-chemokines.

  Brichacek B, Bukrinsky M. Brichacek B, et al. Clin Exp Immunol. 2002 Nov;130(2):169-71. doi: 10.1046/j.1365-2249.2002.02010.x. Clin Exp Immunol. 2002. PMID: 12390302 Free PMC article. No abstract available.
• Antiretroviral therapy for HIV: drug resistance and sequencing.

  Burkle WS. Burkle WS. J Assoc Nurses AIDS Care. 2002 Jan-Feb;13(1):76-80. doi: 10.1016/S1055-3290(06)60243-4. J Assoc Nurses AIDS Care. 2002. PMID: 11828862 Review. No abstract available.
• Drug interactions of antiretroviral agents.

  Kosel BW, Aweeka F. Kosel BW, et al. AIDS Clin Rev. 2000-2001:193-227. AIDS Clin Rev. 2000. PMID: 10999221 Review. No abstract available.